Amgen Inc. said its osteoporosis drug candidate denosumab beat a rival drug in reducing and delaying the rate of fractures in men with prostate cancer during a study. The drug, also called Prolia, is viewed by Wall Street as Amgen's next blockbuster product and a ...

CHICAGO (Reuters) - Being diagnosed with prostate cancer roughly doubles the risk of suicide or death from a heart attack, U.S. researchers said on Tuesday, adding to the harm linked with diagnosis of this often slow-growing cancer. A team at Harvard and Brigham & Women's Hospital in Boston used data from more than 340,000 prostate cancer patients diagnosed ...

WASHINGTON (Reuters) - Prostate cancer treatments that cut off the supply of male hormone raise cholesterol, worsen blood sugar and make men fatter and thus likely raise the risk of heart attack, too, doctors said on Monday. An advisory published in the American Heart Association's journal Circulation recommends that doctors keep a close eye on men they treat with so-called ...